Search results
Journal of Free Speech Law: "FDA Regulation of Physicians’ Professional Speech," by Prof. Barbara J....
Reason.com· 7 hours agoOn September 28, 2022, after six years of effort and two draft guidance documents, the U.S. Food and Drug Administration (FDA) finalized its Guidance on Clinical Decision ...
FDA official: The risk of secondary cancer from CAR-T therapy is less than feared
Medical Xpress· 1 day agoThe risk of secondary cancer after CAR-T therapy, pioneered at Penn, is less than regulators feared...
Alzheimer's in Kern: a new drug is being tested that could bring hope.
KERO 23 Bakersfield· 3 hours agoThe FDA is currently in the process of approving a new drug, that will slow down the affects of Alzheimer's Disease by 18 months. In California alone over 700,000 people are ...
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead...
The Joplin Globe· 1 day ago"We are pleased with the outcome of our recently received feedback from the FDA and are excited to progress the development program for our novel buccal delivery asset, TH104 ...
New Alzheimer's drug brings hope to those dealing with the disease
NewsWest 9· 2 days agoOnce news of the FDA Advisory Council’s recent unanimous endorsement of the drug donanemab reached...
Joe Grogan: Access to new Alzheimer’s treatments bogged down by Medicare policy
Chicago Tribune· 2 days agoAlzheimer’s is a progressive, fatal disease that boggled scientists for a century. Now, at last, we...
... Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's...
Benzinga· 7 days agoJim Cramer has expressed his confidence in Eli Lilly and Co LLY, citing the company’s diverse drug...
Some hawking stem cells say they can treat almost anything. They can't - KVIA
ABC 7 El Paso· 4 days agoIowa is among the states suing companies raking in millions by injecting people with stem cells that the Federal Drug Administration...One expert told The Associated Press many stem cells injected ...
Two Is Better Than One in the Alzheimer’s Market
The Wall Street Journal via Yahoo Finance· 1 day agoUnderscoring that point, Biogen’s shares are up slightly more than Lilly’s since the FDA panel meeting. Leqembi and donanemab both work in Alzheimer’s...
Céline Dion’s Doctor Makes Plea for More Stiff-Person Syndrome Research (Exclusive)
People via Yahoo News· 2 days ago“The awareness that we see with Céline bringing this to the general population… people are going to...
